Cargando…

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments

Background Bladder cancer is an important public health concern due to its prevalence, high risk of recurrence and associated cost of management. Although BCG instillation for urothelial cancer treatment is the gold-standard treatment for this indication, repeated BCG treatments are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Sylvain, Chevalier, Mathieu F, Benmerzoug, Sulayman, Cesson, Valérie, Schneider, Anna K, Rodrigues-Dias, Sonia-Cristina, Dartiguenave, Florence, Lucca, Ilaria, Jichlinski, Patrice, Roth, Beat, Nardelli-Haefliger, Denise, Derré, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413168/ https://www.ncbi.nlm.nih.gov/pubmed/36002184 http://dx.doi.org/10.1136/jitc-2022-004880

Ejemplares similares

Siglec-7 May Limit Natural Killer Cell–mediated Antitumor responses in Bladder Cancer Patients
por: Benmerzoug, Sulayman, et al.
Publicado: (2021)

Double Positive CD4(+)CD8(+) T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization
por: Bohner, Perrine, et al.
Publicado: (2019)

Intravesical Ty21a Treatment of Non–muscle-invasive Bladder Cancer Shows a Good Safety Profile
por: Lucca, Ilaria, et al.
Publicado: (2022)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Immunotherapeutic strategies for bladder cancer
por: Chevalier, Mathieu F, et al.
Publicado: (2014)

Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients
por: Pieraerts, Claire, et al.
Publicado: (2012)

Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies
por: Domingos-Pereira, Sonia, et al.
Publicado: (2022)

Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8(+) T cells
por: Decrausaz, Loane, et al.
Publicado: (2013)

What is the influence of vaccination’s routes on the regression of tumors located at mucosal sites?
por: Nardelli-Haefliger, Denise, et al.
Publicado: (2012)

Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion
por: Alonso, Florian, et al.
Publicado: (2016)

Intravaginal TLR agonists increase local vaccine-specific CD8 T-cells and human papillomavirus-associated genital-tumor regression in mice
por: Domingos-Pereira, Sonia, et al.
Publicado: (2012)

Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer
por: Hojeij, Rim, et al.
Publicado: (2016)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
por: Ji, Niannian, et al.
Publicado: (2021)

Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
por: Wang, Sheng, et al.
Publicado: (2023)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

Methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer by triggering endoplasmic reticulum stress and cGAS-STING activation
por: Zhou, Han, et al.
Publicado: (2023)

Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer
por: Di Mascolo, Daniele, et al.
Publicado: (2019)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Myeloid cell TNFR1 signaling dependent liver injury and inflammation upon BCG infection
por: Chavez-Galan, Leslie, et al.
Publicado: (2019)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth
por: Sathiyanadan, Karthik, et al.
Publicado: (2022)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma
por: Pinjusic, Katarina, et al.
Publicado: (2022)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2(+) T cells compared with the aminobisphosphonate drug zoledronic acid
por: Fenn, J, et al.
Publicado: (2022)

Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer
por: Wang, Qinchuan, et al.
Publicado: (2020)

Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
por: Horie, N, et al.
Publicado: (2007)

BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma
por: Kremenovic, Mirela, et al.
Publicado: (2022)

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
por: Jung, Jaeyun, et al.
Publicado: (2023)

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
por: Duivenvoorden, W C M, et al.
Publicado: (2007)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
por: Gunelli, R, et al.
Publicado: (2007)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2021)

Vaccination with BCGΔBCG1419c protects against pulmonary and extrapulmonary TB and is safer than BCG
por: Aceves-Sánchez, Michel de Jesús, et al.
Publicado: (2021)

Heparin Prowess: Favorable Vascular–Immune Reprogramming in Pancreatic Cancer
por: Korc, Murray
Publicado: (2023)

Genome sequences of BCG Pasteur ATCC 35734 and its derivative, the vaccine candidate BCGΔBCG1419c
por: D’Auria, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8oscbmitrro1bh46f4nt4kl764